What is the Share Price of Fredun Pharmaceuticals Ltd?
- Answer Field
-
The share price of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 695.40.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, Fredun Pharmaceuticals Limited share price is currently at ₹ 701.95, which is down by ₹ -1.39 from its previous closing. Today, the stock has fluctuated between ₹ 694.05 and ₹ 705.00. Over the past year, Fredun Pharmaceuticals Limited has achieved a return of -25.67 %. In the last month alone, the return has been -0.47 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 101.84 |
Operating Expense | 95.56 |
Net Profit | 5.33 |
Net Profit Margin (%) | 5.23 |
Earnings Per Share (EPS) | 11.29 |
EBITDA | 13.21 |
Effective Tax Rate (%) | 25.24 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
GLAXOSMITHKLINE PHARMA LT | 2959.45 | 58.70 | 29.97 | 50134.87 | 1924.30 / 3147.45 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals (FPL) was converted into a public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL.
The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems.
The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind.
In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden.
Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka.
In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category.
The share price of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 695.40.
The market cap of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 3,28.30 Cr. as of now.
The 52 Week High and Low of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 1024.00 and ₹ 635.00.
You can trade in Fredun Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been -25.67%.
Fredun Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 695.40 as on Apr 30 2025 03:25 PM.
The market cap of Fredun Pharmaceuticals Ltd for NSE ₹ 0.0 & for BSE ₹ 3,28.30 as on Apr 30 2025 03:25 PM.
As on Apr 30 2025 03:25 PM the price-to-earnings (PE) ratio for Fredun Pharmaceuticals Ltd share is 17.47.
As on Apr 30 2025 03:25 PM, the price-to-book (PB) ratio for Fredun Pharmaceuticals Ltd share is 277.17.
You can trade in Fredun Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.
To buy Fredun Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Fredun Pharmaceuticals Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found